Literature DB >> 16527881

Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again).

C M Deighton, E George, P D W Kiely, J Ledingham, R A Luqmani, D G I Scott.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16527881     DOI： 10.1093/rheumatology/kel053

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  5 in total

1.  Anti-tumor necrosis factor therapy and influenza: keeping it in perspective.

Authors:  Matt Shale; Markus Czub; Gilaad G Kaplan; Remo Panaccione; Subrata Ghosh
Journal:  Therap Adv Gastroenterol       Date:  2010-05       Impact factor: 4.409

2.  The use of low-dose etanercept as an alternative therapy for treatment of ankylosing spondylitis: a case series.

Authors:  Jamileh Moghimi; Mehrdad Sheikhvatan; Vahid Semnani
Journal:  Rheumatol Int       Date:  2011-05-08       Impact factor: 2.631

3.  Surgery during etanercept therapy in patients with rheumatoid arthritis: is it time to follow patient preferences?

Authors:  Salvatore Corrao; Giovanni Pistone; Sabrina Arnone; Luigi Calvo; Rosario Scaglione; Giuseppe Licata
Journal:  Intern Emerg Med       Date:  2008-02-13       Impact factor: 3.397

Review 4.  Tocilizumab: a review of its use in the management of rheumatoid arthritis.

Authors:  Vicki Oldfield; Sohita Dhillon; Greg L Plosker
Journal:  Drugs       Date:  2009       Impact factor: 9.546

5.  Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry.

Authors:  Matteo Filippini; Chiara Bazzani; Fabiola Atzeni; Piercarlo Sarzi Puttini; Antonio Marchesoni; Ennio Giulio Favalli; Roberto Caporali; Lorenzo Cavagna; Roberto Gorla
Journal:  Biomed Res Int       Date:  2014-07-06       Impact factor: 3.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.